LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

Pacira Pharmaceuticals Inc-DE

Closed

SectorHealthcare

23.59 -1.17

Overview

Share price change

24h

Current

Min

23.31

Max

23.98

Key metrics

By Trading Economics

Income

-11M

4.8M

Sales

-18M

169M

P/E

Sector Avg

11.23

50.291

EPS

0.62

Profit margin

2.849

Employees

788

EBITDA

-17M

34M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+72.52% upside

Dividends

By Dow Jones

Next Earnings

29 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-88M

1.1B

Previous open

24.76

Previous close

23.59

News Sentiment

By Acuity

50%

50%

165 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Pacira Pharmaceuticals Inc-DE Chart

Past performance is not a reliable indicator of future results.

Related News

7 Apr 2025, 23:45 UTC

Hot Stocks

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

2 Jul 2024, 16:22 UTC

Major Market Movers

Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic

Peer Comparison

Price change

Pacira Pharmaceuticals Inc-DE Forecast

Price Target

By TipRanks

72.52% upside

12 Months Forecast

Average 41.25 USD  72.52%

High 65 USD

Low 26 USD

Based on 7 Wall Street analysts offering 12 month price targets forPacira Pharmaceuticals Inc-DE - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

3

Buy

3

Hold

1

Sell

Technical Score

By Trading Central

24.83 / 26.38Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

165 / 380 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.